Last updated on April 17, 2014 at 21:23 EDT

Caprion Collaboration with Indi on Development of Blood-Based Diagnostic for Lung Cancer Yields Publication in Science Translational Medicine

October 16, 2013

Breakthrough Technology Powered by Advanced MRM-Mass Spec Protein
Detection Provides Scientific Validation of Caprion’s Proteomics
Biomarker Discovery Technologies and Partnership-Driven Business Model

MONTREAL, Oct. 16, 2013 /PRNewswire/ – Caprion Proteomics announced
today the results of a major study conducted by Indi (Integrated
Diagnostics), an emerging leader in molecular diagnostics that has been
actively collaborating with Caprion since 2008, which suggests that
quantification of a combination of blood proteins can accurately
distinguish between benign lung nodules and early-stage lung cancer.
The study, which was published today in Science Translational Medicine
(STM) and includes several Caprion scientists as co-authors, indicates
that when the relative concentrations of this group of proteins (or
‘classifier’) is combined, the classifier result is correct more than
90 percent of the time in diagnosing benign lung nodules. This multiple
protein classifier uses a highly sensitive analytic technique called
multiple reaction monitoring mass spectroscopy (MRM-mass spec). The
laboratory-based analytical method, combined with sophisticated
bioinformatics and systems-biology approaches allowed the researchers
to assess the diagnostic power of 371 potential lung cancer biomarkers
in millions of different combinations before settling on the diagnostic
classifier (set of biomarkers) that these data indicate is most

“These studies suggest that Indi’s technology is capable of detecting
the molecular signature of lung cancer by measuring the presence of
multiple proteins in a patient’s blood,” said Paul Kearney, Ph.D.,
President and Chief Science Officer, Indi and senior author of the STM
paper. “We are very pleased that these data show we have achieved a 90
percent probability with this diagnostic classifier. Doing so required
performing an unbiased search for biomarkers involved in early-stage
lung cancer, considering all potential disease pathways. Using MRM-mass
spec as the platform was essential because it makes it feasible to
simultaneously measure hundreds of proteins at once. Conducting the
broadest possible search for biomarkers allowed us to find the group
with the greatest diagnostic value.”

Caprion has been an early-day scientific collaborator and provider of
proteomics services to Indi on this study. Caprion’s involvement
included the use of its CellCarta(®) proteomics technology for the initial discovery of candidate biomarkers
using a tissue-based proteomics approach on purified plasma membranes
and secretory vesicles isolated from human lung cancer tissue
specimens. Subsequently, Caprion performed the initial development and
deployment of the MRM assay used to detect the presence of 371
potential lung cancer biomarkers in the blood.

“We congratulate Indi on the results of the study which we believe
represent a major scientific advance for the field of proteomics as
well as tangible evidence of the highly productive and collaborative
partnership that Caprion has established with Indi over the past 5
years.said Martin LeBlanc, Caprion’s President and Chief Executive Officer.
“The findings of the study also provide solid scientific validation for
Caprion’s proteomics platform, expertise and services in the discovery
and validation of biomarkers. These results pave the way for the future
deployment of other innovative proprietary protein diagnostic tests for
metabolic and infectious diseases that are being developed by Caprion
using its CellCarta(®) proteomics technologies.”

In addition to Indi and Caprion, the STM paper, which is titled “A
Blood-Based Proteomic Classifier for the Molecular Characterization of
Pulmonary Nodules”, also included the participation and/or the
provision of clinical specimens from investigators and collaborators at
Institute for Systems Biology (ISB), the British Columbia Cancer
Agency, ISB, the Institut Universitaire de Cardiologie et de
Pneumologie de Quebec, the New York University Langone Medical Center
and School of Medicine, the Perelman School of Medicine at the
University of Pennsylvania, and the Vanderbilt University Medical

About Caprion Proteomics

Caprion is the leading provider of proteomics biomarker and immune
monitoring services to the pharmaceutical and biotechnology industry.
Its proprietary proteomics technology, CellCarta(®), is a gel-free, label-free mass spectrometry (MS) platform that enables
a comprehensive, quantitative and robust comparative measurement of
proteins across large sets of biological samples for the discovery and
validation of protein biomarkers. Its proprietary immune monitoring
platform, ImmuneCarta(®), offers multiparametric flow cytometry analysis for functional analyses
of innate and adaptive immune responses. Caprion also leverages
CellCarta(®) to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research
sites in Montreal, Canada and in Menlo Park, CA, Caprion has been
providing large-scale proteomics and immune monitoring services to over
50 major pharmaceutical and biotech clients for more than 10 years.
Caprion also serves as a biomarker center of excellence for the U.S.
Government/NIH-NIAID for Biodefense research. Caprion acquired PPD
Biomarker Discovery Sciences, LLC from PPD Inc. in 2010, and the assets
of the National Immune Monitoring Laboratory in 2011. Caprion
Proteomics, a privately-held company, is majority owned by Chicago
Growth Partners. For more information, please visit www.caprion.com.

About Indi

Indi (Integrated Diagnostics) is creating powerful new tools to help
physicians manage complex diseases with a non-invasive blood test. The
company’s first test measures multiple blood proteins linked to
pulmonary nodules. The aim of the test is to help physicians identify
patients whose nodules are likely to be benign, eliminating the risks
they face from biopsies and surgeries. www.IndiDx.com

The company, co-founded in October 2009 by systems-biology pioneer Dr.
Lee Hood, is conceptually based on a systems view of disease where
pathophysiology arises from disease-perturbed networks of proteins,
genes, and other molecules. Investors include InterWest Partners and
The Wellcome Trust. Foundational intellectual property is exclusively
licensed from the Institute for Systems Biology and Caltech. Learn more
at www.indidx.com

SOURCE Caprion Proteomics

Source: PR Newswire